【摘要】 目的　探讨替尼泊甙 (teniposide ,VM 2 6 )这一鬼臼毒植物碱类化疗药物对口腔鳞癌的体外抗瘤效果 ,为其治疗口腔鳞癌提供实验依据。方法　有 81例纳入研究的患者 ,切取经病理证实的口腔鳞癌术后标本或活检标本行体外药敏检测。检测VM 2 6时以顺铂 (cisplatin ,CDDP)作对照 ,药物应用 5倍的峰血浆浓度。VM 2 6终浓度为 6 0mg/L ,CDDP为 15mg/L。结果　 81例标本完成药敏检测 75例 ,药敏检测成功率为 92 .6 %。 75例患者按UICC标准的TNM分期结果为 :I期 2例 ,II期 11例 ,III期 34例 ,IV2 8例。这组患者病理分级结果为I级 18例 ,I～II级 37例 ,III级 2 0例。VM 2 6和CDDP对口腔鳞癌细胞的生长抑制率分别为 6 3.34%和 2 4 .0 8%,前者生长抑制率明显高于后者 (P <0 .0 1)。结论　VM 2 6对口腔鳞癌的抗瘤敏感性明显高于CDDP ,VM 2 6有望成为治疗口腔鳞癌的首选化疗药物。更多还原

【Abstract】 Objective To investigate the antitumor effectiveness of teniposide in oral squamous cell carcinomas (OSCC) and to find evidence for using teniposide for treatment of patients with OSCC. Methods Seventy-five patients with OSCC from the School of Stomatology,Shanghai Second medical University during 1999 to 2001 were evaluated. Tumors were diagnosed pathologically, and drug sensitivity tested. The antitumor drugs tested were cisplatin (CDDP) and teniposide (VM-26). Fresh drug was diluted in complete medium at fold of five times of peak plasma concentration (PPC×5) achieved by intravenous administration of clinical doses. The concentrations were VM-26 60 mg/L, CDDP 15 mg/L. Results The MTT assay was performed in 75 of 81 patients (success rate 92.6%). The clinical stages of the 75 patients according to the UICC TNM classification of malignant tumors were 28 with stage IV, 34 with stage III, 11 with stage II and 2 with stage I. The pathological grades of the 75 patients according to three step classification were 18 with Grade I, 37 with Grade I～II and 20 with Grade III. At a drug concentration of PPC×5, the inhibition rates of tumor cells for VM-26 and CDDP were 63.34% and 24.08%, respectively. The inhibition rates of tumor cells for VM-26 were significantly higher than those for CDDP ( P <0.01). Conclusions The inhibition rates of OSCC cells for VM-26 are significantly higher than for CDDP. VM-26 may be the first selected drug for treating patients with OSCC.更多还原